A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2006
06/22/2006	US20060135619 2-[(3-chloro-4-hydroxybenzoyl)amino]-N-[2-(2-methoxyphenyl)ethyl]-5-phenoxybenzamide; therapeutic use as anti-cancer agents, as well as other therapeutic agents, for example, as anti-fertility agents
06/22/2006	US20060135459 Targeted innate immunity
06/22/2006	US20060135454 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
06/22/2006	US20060135430 BLy antagonists and uses thereof
06/22/2006	US20060134682 Preparation and use of superior vaccines
06/22/2006	US20060134668 Methods for treating patients and identifying therapeutics
06/22/2006	US20060134632 Oligonucleotides and methods for detecting hepatitis C viral nucleic acids
06/22/2006	US20060134622 Amplified cancer target genes useful in diagnosis and thereapeutic screening
06/22/2006	US20060134232 Herbal supplement for cognitive related impairment due to estrogen loss
06/22/2006	US20060134143 Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
06/22/2006	US20060134142 Modified streptococcal polysaccharides and uses thereof
06/22/2006	US20060134141 Glycoconjugate vaccines containing peptidoglycan
06/22/2006	US20060134140 Compositions and methods for treating tumor spreading
06/22/2006	US20060134139 Dried product and a process for manufacturing the product
06/22/2006	US20060134138 Recombinant influenza viruses for vaccines and gene therapy
06/22/2006	US20060134137 Transduction vector based on modified HIV-2
06/22/2006	US20060134136 Whole bacterial cells as immune modulator
06/22/2006	US20060134135 Bacterial virulence genes
06/22/2006	US20060134134 Method of obatining cochlear structures, vaccine compositions, adjuvants and interme- diates thereof
06/22/2006	US20060134133 An immunogenic composition containing modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes
06/22/2006	US20060134130 Oral drug delivery compositions and methods
06/22/2006	US20060134129 Anticancer agents; leukemia
06/22/2006	US20060134128 Screening for an inhibitor of binding between human Toll-like receptor 3 and a protein of specific amino acid sequence by contacting a candidate with a transfected cell encoding the protein which expresses the receptor; increased interferon in vivo; antitumor, autoimmune agents; side effect reduction
06/22/2006	US20060134127 Antiallergic agent
06/22/2006	US20060134126 Peptide constructs for treating disease
06/22/2006	US20060134125 Purification of antigen-specific T cells
06/22/2006	US20060134124 Immunosuppression
06/22/2006	US20060134122 Peptides of syndecan-1 for inhibition of cancer
06/22/2006	US20060134121 DII4 antagonists, assays, and therapeutic methods thereof
06/22/2006	US20060134120 Multiple marker assay for detection of ovarian cancer
06/22/2006	US20060134119 Drugs containing galectin 9
06/22/2006	US20060134118 using a monoclonal antibody or an antigen-binding portion which binds to an epitope of EphB4 polypeptide and inhibiting the growth of cancer as a result of such binding by causing cell death
06/22/2006	US20060134117 Preventives/remedies for cancer
06/22/2006	US20060134116 Ca 125 tumor antigen function and uses thereof
06/22/2006	US20060134115 Method of screening for sensitivity to kinase inhibitor therapy
06/22/2006	US20060134114 Novel human kallikrein-like genes
06/22/2006	US20060134113 Preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
06/22/2006	US20060134112 Uses of mammalian cytokine; related reagents
06/22/2006	US20060134111 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
06/22/2006	US20060134110 CD55-Interaction partners and the uses thereof
06/22/2006	US20060134109 G protein coupled receptors and uses thereof
06/22/2006	US20060134108 Method for retarding or precluding Alzheimer's dementia
06/22/2006	US20060134107 Immunoglobulins devoid of light chains
06/22/2006	US20060134106 Antibody composition and passive immunization against pregnancy-induced hypertension
06/22/2006	US20060134105 IgG immunoglobulin variants with optimized effector function
06/22/2006	US20060134104 for identifying and/or using inhibitors of the HGF/c-met signaling pathway; a mesenchyme-derived pleiotrophic factor with mitogenic, motogenic and morphogenic activities on a number of different cell types
06/22/2006	US20060134103 Compounds and molecular complexes comprising multiple binding regions directed to transcytotic ligands
06/22/2006	US20060134102 Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
06/22/2006	US20060134101 Use of avian antibodies
06/22/2006	US20060134100 Dc-sign blockers and their use for preventing or treating viral infections
06/22/2006	US20060134099 Production of rabies antibodies in plants
06/22/2006	US20060134098 Immunoglobulin variable region cassette exchange
06/22/2006	US20060134067 Loading of cells with antigens by electroporation
06/22/2006	US20060134065 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
06/22/2006	US20060133994 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
06/22/2006	CA2634589A1 Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising this fragment for detecting, preventing, and treating hiv
06/22/2006	CA2592366A1 Recombinant foot and mouth disease vaccine
06/22/2006	CA2591918A1 Cancer-specific spanx-n markers
06/22/2006	CA2591716A1 Identification and use of prognostic and predictive markers in cancer treatment
06/22/2006	CA2591668A1 Pharmaceutical composition comprising a bacterial cell displaying a heterologous proteinaceous compound
06/22/2006	CA2591659A1 Regulation of metalloprotease cleavage of cell surface proteins
06/22/2006	CA2591442A1 Glycoconjugate vaccines containing peptidoglycan
06/22/2006	CA2591421A1 Novel efficient production process for capsular polysaccharides of pathogenic grampositive bacteria by heterologous expression and secretion of complex polysaccharides in non-pathogenic, non-invasive gram- positive bacteria
06/22/2006	CA2591044A1 Adjuvant activity of gastrointestinal peptides
06/22/2006	CA2590935A1 Fc.gamma.riib-specific antibodies and methods of use thereof
06/22/2006	CA2590906A1 Deacylation of lps in gram negative bacteria
06/22/2006	CA2590778A1 Il-15 antigen arrays and uses thereof
06/22/2006	CA2590431A1 Novel pharmaceutical composition containing at least one dolastatin 10 derivative
06/22/2006	CA2590369A1 Compositions comprising sclareol or derivatives thereof and uses thereof
06/22/2006	CA2590337A1 Humanized amyloid beta antibodies for use in improving cognition
06/22/2006	CA2590303A1 Cytotoxic antibody directed against type b lymphoid hematopoietic proliferations
06/22/2006	CA2589975A1 Releasable polymeric conjugates based on aliphatic biodegradable linkers
06/22/2006	CA2589698A1 Improved dna immunization with recombinase/transposase
06/22/2006	CA2589553A1 Use of flagellin in the immunotherapy of yersinia pestis
06/22/2006	CA2589521A1 Combinations of 7-t-butoxyiminomethylcamptothecin with one or more chemotherapeutic agents for treating cancers
06/22/2006	CA2589359A1 Targeted iron chelator delivery system
06/22/2006	CA2589017A1 Amyloid beta antibodies for use in improving cognition
06/22/2006	CA2587932A1 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
06/21/2006	EP1672368A1 Diagnostic and therapeutic epitope and transgenic plant
06/21/2006	EP1672072A2 Cloning and characterisation of the gene flbA of H. pylori; production of flagella-free strains
06/21/2006	EP1671981A2 Nucleic acids and proteins from streptococcus group A
06/21/2006	EP1671648A1 Prevention and treatment for gvhd
06/21/2006	EP1671646A2 Methods of treating IgE-associated disorders and compositions for use therein
06/21/2006	EP1671625A1 Nanoparticles
06/21/2006	EP1670926A2 Modified cea /b7 vector
06/21/2006	EP1670899A2 Vaccines for cancer, autoimmune disease and infections
06/21/2006	EP1670894A2 Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
06/21/2006	EP1670893A2 Immunogenic hiv compositions and related methods
06/21/2006	EP1670828A1 Fully human antibodies against human 4-1bb (cd137)
06/21/2006	EP1670825A2 Antibodies to m-csf
06/21/2006	EP1670824A2 Norovirus monoclonal antibodies and peptides
06/21/2006	EP1670820A2 Antigens for an east coast fever vaccine
06/21/2006	EP1670818A2 Piscirickettsia salmonis antigens and use thereof
06/21/2006	EP1670812A2 Ozonation products of cholesterol for the treatment and prevention of atherosclerosis and/or cardiovascular diseases
06/21/2006	EP1670513A2 Use of cox-2 inhibitor to prevent t-cell anergy induced by dendritic cell therapy
06/21/2006	EP1670511A2 Cripto antagonism of activin and tgf-b signaling
06/21/2006	EP1670509A2 Multiplex vaccines
06/21/2006	EP1670508A2 Compositions, methods and kits relating to poxvirus subunit vaccines
06/21/2006	EP1670507A2 Vaccine for treatment and prevention of herpes simplex virus infection
06/21/2006	EP1670506A2 Liquid vaccines for multiple meningococcal serogroups

1 ... 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 ... 1823